Oxaliplatin-induced portal hypertension manifesting as portosystemic shunt: A case report and review of sinusoidal obstruction syndrome in gastric cancer
{"title":"Oxaliplatin-induced portal hypertension manifesting as portosystemic shunt: A case report and review of sinusoidal obstruction syndrome in gastric cancer","authors":"Toshimitsu Ichimaru, Takamitsu Sakamoto, Teruyoshi Amagai","doi":"10.1002/deo2.70109","DOIUrl":null,"url":null,"abstract":"<p>A 77-year-old woman with stage IVB gastric adenocarcinoma (cT4N2M1) received 10 cycles of S-1, oxaliplatin, and nivolumab combination chemotherapy. Imaging and biopsy confirmed a complete response. However, thrombocytopenia, mild splenomegaly, and elevated liver enzymes developed following oxaliplatin administration. After the tenth cycle, a contrast-enhanced computed tomography scan revealed a portosystemic shunt. Oxaliplatin was discontinued, but the shunt persisted after 1 year. Balloon-occluded retrograde transvenous obliteration was successfully performed, resulting in the resolution of the shunt. This case highlights the potential for oxaliplatin-induced portal hypertension requiring close monitoring.</p>","PeriodicalId":93973,"journal":{"name":"DEN open","volume":"5 1","pages":""},"PeriodicalIF":1.4000,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/deo2.70109","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"DEN open","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/deo2.70109","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
A 77-year-old woman with stage IVB gastric adenocarcinoma (cT4N2M1) received 10 cycles of S-1, oxaliplatin, and nivolumab combination chemotherapy. Imaging and biopsy confirmed a complete response. However, thrombocytopenia, mild splenomegaly, and elevated liver enzymes developed following oxaliplatin administration. After the tenth cycle, a contrast-enhanced computed tomography scan revealed a portosystemic shunt. Oxaliplatin was discontinued, but the shunt persisted after 1 year. Balloon-occluded retrograde transvenous obliteration was successfully performed, resulting in the resolution of the shunt. This case highlights the potential for oxaliplatin-induced portal hypertension requiring close monitoring.